Literature DB >> 12694338

A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients.

Roberto Pecoits-Filho1, Peter Stenvinkel, Alicia Marchlewska, Olof Heimburger, Peter Bárány, Catherine M Hoff, Clifford J Holmes, Mohamed Suliman, Bengt Lindholm, Martin Schalling, Louise Nordfors.   

Abstract

Cardiovascular disease (CVD) is the leading cause of mortality in end-stage renal disease (ESRD) patients and there is emerging evidence that genetic factors may contribute to the development of atherosclerosis. Myeloperoxidase (MPO) is an abundant enzyme involved in the production of free radicals. A functional G-->A single nucleotide polymorphism (SNP) has been identified at position -463, where the A allele is associated with lower MPO expression. To analyze the association between this SNP and inflammation, oxidative stress, and CVD, we studied a cohort of 155 ESRD patients (52 +/- 1 years, 62% males, 22% diabetics) shortly before the initiation of dialysis treatment. CVD was defined by medical history criteria; plasma interleukin-6 (IL-6) was used as a marker of inflammation, and plasma pentosidine as an estimation of oxidative protein damage. DNA from leukocytes was used for genotyping, performed by the pyrosequencing reaction. Only five patients (3%) had the genotype AA at the -463 position, whereas 38 (25%) had the GA and 112 (72%) had the GG genotype. No differences were noted in plasma IL-6 levels between the genotype groups, whereas the pentosidine levels were higher in the GG group (28.4 pmol/mg albumin [range, 8.5 to 123 pmol/mg albumin]) compared to the other two groups (21.4 pmol/mg albumin [range, 7.6 to 384 pmol/mg albumin; P < 0.05]). Patients with the GG genotype had a higher prevalence of positive serology for Chlamydia pneumoniae (51%) when compared to the carriers of the A allele (24%) (P < 0.05). The prevalence of CVD was lower in the AA (0%) and GA genotypes (18%), compared to the GG genotype (35%). The GG genotype was still associated with CVD after correction for age, diabetes, smoking, malnutrition, and inflammation. Our findings suggest that the -463 G-->A SNP, which supposedly results in lower MPO activity, is associated with a lower prevalence of CVD in ESRD patients. It could be speculated that this effect is mediated by a decreased oxidative stress due to lower production of free radicals.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12694338     DOI: 10.1046/j.1523-1755.63.s84.32.x

Source DB:  PubMed          Journal:  Kidney Int Suppl        ISSN: 0098-6577            Impact factor:   10.545


  28 in total

Review 1.  Inflammatory and oxidative markers in atherosclerosis: relationship to outcome.

Authors:  Mehdi H Shishehbor; Stanley L Hazen
Journal:  Curr Atheroscler Rep       Date:  2004-05       Impact factor: 5.113

2.  Oxidative balance and colon and rectal cancer: interaction of lifestyle factors and genes.

Authors:  Martha L Slattery; Abbie Lundgreen; Bill Welbourn; Roger K Wolff; Christopher Corcoran
Journal:  Mutat Res       Date:  2012-04-15       Impact factor: 2.433

3.  Effects of MPO-463G/A and -129G/A polymorphisms on coronary artery disease risk and patient survival in a Turkish population.

Authors:  Serdal Arslan; Öcal Berkan; Burcu Bayyurt; Osman Beton; Ni L Özbi Lüm Şahin; Eylem Itır Aydemir
Journal:  Biomed Rep       Date:  2017-10-03

4.  Human myeloperoxidase (hMPO) is expressed in neurons in the substantia nigra in Parkinson's disease and in the hMPO-α-synuclein-A53T mouse model, correlating with increased nitration and aggregation of α-synuclein and exacerbation of motor impairment.

Authors:  Richard A Maki; Michael Holzer; Khatereh Motamedchaboki; Ernst Malle; Eliezer Masliah; Gunther Marsche; Wanda F Reynolds
Journal:  Free Radic Biol Med       Date:  2019-06-06       Impact factor: 7.376

Review 5.  The use of myeloperoxidase as a risk marker for atherosclerosis.

Authors:  Vijay Nambi
Journal:  Curr Atheroscler Rep       Date:  2005-03       Impact factor: 5.113

6.  Risk prediction with serial myeloperoxidase monitoring in patients with acute chest pain.

Authors:  Stephen J Nicholls; W H Wilson Tang; Danielle Brennan; Marie-Luise Brennan; Shirley Mann; Steven E Nissen; Stanley L Hazen
Journal:  Clin Chem       Date:  2011-09-22       Impact factor: 8.327

7.  The effect of N-acetylcysteine on oxidative serum biomarkers of hemodialysis patients.

Authors:  I Giannikouris
Journal:  Hippokratia       Date:  2015 Apr-Jun       Impact factor: 0.471

8.  Distribution of oxidation enzyme eNOS and myeloperoxidase in primary open angle glaucoma.

Authors:  Hui-Ju Lin; Chang-Hai Tsai; Fuu-Jen Tsai; Wei-Cheng Chen; Shih-Wei Tsai; Seng-Sheen Fan
Journal:  J Clin Lab Anal       Date:  2005       Impact factor: 2.352

9.  Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease.

Authors:  Lemin Zheng; Benedicta Nukuna; Marie-Luise Brennan; Mingjiang Sun; Marlene Goormastic; Megan Settle; Dave Schmitt; Xiaoming Fu; Leonor Thomson; Paul L Fox; Harry Ischiropoulos; Jonathan D Smith; Michael Kinter; Stanley L Hazen
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

10.  Association of the G-463A myeloperoxidase gene polymorphism with renal disease in African Americans with systemic lupus erythematosus.

Authors:  Henda Bouali; Paul Nietert; Tamara M Nowling; Janardan Pandey; Mary Anne Dooley; Glinda Cooper; John Harley; Diane L Kamen; Jim Oates; Gary Gilkeson
Journal:  J Rheumatol       Date:  2007-09-15       Impact factor: 4.666

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.